The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Authors: Vaz Batista, Marta ^{1, 2, 17}, Pérez-García, José Manuel ^{2, 3, 17}, Garrigós, Laia ^{3, 4}, García-Sáenz, José Ángel ⁵, Cortez, Patricia ⁶, Racca, Fabricio ⁷, Blanch, Salvador ^{2, 8}, Ruiz-Borrego, Manuel ⁹, Fernández-Ortega, Adela ¹⁰, Fernández-Abad, María ^{11, 12}, Iranzo, Vega ¹³, Gion, María ¹¹, Martrat, Griselda ², Alcalá-López, Daniel ², Pérez-Escuredo, Jhudit ², Sampayo-Cordero, Miguel ², Llombart-Cussac, Antonio ^{2, 14, 15, ∗}, Braga, Sofia ¹, Cortés, Javier ^{2, 3, 16, 18, ∗∗}

Source: In Med 10 January 2025 6(1)

Influence of binge drinking on the resting state functional connectivity of university Students: A follow-up study

Authors: Suárez-Suárez, Samuel ^a, Cadaveira, Fernando ^{b, c}, Barrós-Loscertales, Alfonso ^d, Pérez-García, José Manuel ^e, Holguín, Socorro Rodríguez ^{b, c}, Blanco-Ramos, Javier ^{e, f}, Doallo, Sonia ^{b, c, ⁎}

Source: In Addictive Behaviors Reports June 2025 21

Neurostructural features predict binge drinking in emerging adulthood: Evidence from a 5-year follow-up study

Authors: Pérez-García, Jose Manuel ^c, Suárez-Suárez, Samuel ^{a, d, ⁎}, Rodríguez González, María Soledad ^{b, d}, Rodríguez Holguín, Socorro ^{a, d}, Cadaveira, Fernando ^{a, d}, Doallo, Sonia ^{a, d}

Source: In Drug and Alcohol Dependence 1 December 2024 265

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

Authors: Alés-Martínez, José Enrique, Balmaña, Judith, Sánchez-Rovira, Pedro, Salvador Bofill, Francisco Javier, García Sáenz, Jose Ángel, Pimentel, Isabel, Morales, Serafín, Fernández-Abad, María, Lahuerta Martínez, Ainhara, Ferrer, Neus, Zamora, Pilar, Bermejo, Begoña, Díaz-Redondo, Tamara, López-Ceballos, María Helena, Galán, María, Pérez-Escuredo, Jhudit, Calabuig, Laura, Sampayo, Miguel, Pérez-Garcia, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

Source: In The Breast October 2024 77

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Authors: Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J., Ruiz-Borrego, Manuel, Gavilá, Joaquín, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez de Dueñas, Eduardo, Amillano, Kepa, Shimizu, Eileen, Sampayo-Cordero, Miguel, Cortés, Javier, Llombart-Cussac, Antonio

Source: In The Breast August 2024 76

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Authors: Llombart-Cussac, Antonio, Pérez-Garcia, José Manuel, Ruiz Borrego, Manuel, Tolosa, Pablo, Blanch, Salvador, Fernández-Ortega, Adela, Urruticoechea, Ander, Blancas, Isabel, Saura, Cristina, Rojas, Beatriz, Bermejo, Begoña, Ponce Lorenzo, José, Gion, María, Cortez-Castedo, Patricia, Llabres, Elisenda, Galve, Elena, Cueva, Juan Fernando, López, Ana, Alonso-Romero, José Luis, González-Santiago, Santiago, Martínez de Dueñas, Eduardo, Ciruelos, Eva, Martrat, Griselda, Gener, Petra, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Gómez-Peralta, Fernando, Cortés, Javier

Source: In eClinicalMedicine May 2024 71

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Authors: Pérez-García, José Manuel ^*, Cortés, Javier ^*, Ruiz-Borrego, Manuel, Colleoni, Marco, Stradella, Agostina, Bermejo, Begoña, Dalenc, Florence, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Marmé, Frederik, Cortés, Alfonso, Albacar, Cinta, Gebhart, Geraldine, Prat, Aleix, Kerrou, Khaldoun, Schmid, Peter, Braga, Sofia, Di Cosimo, Serena, Gion, Maria, Antonarelli, Gabriele, Popa, Crina, Szostak, Emilia, Alcalá-López, Daniel, Gener, Petra, Rodríguez-Morató, Jose, Mina, Leonardo, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio ^*

Source: In The Lancet 27 April-3 May 2024 403(10437):1649-1659

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Authors: Hurvitz, Sara A ^*, Hegg, Roberto, Chung, Wei-Pang, Im, Seock-Ah, Jacot, William, Ganju, Vinod, Chiu, Joanne Wing Yan, Xu, Binghe, Hamilton, Erika, Madhusudan, Srinivasan, Iwata, Hiroji, Altintas, Sevilay, Henning, Jan-Willem, Curigliano, Giuseppe, Perez-Garcia, José Manuel, Kim, Sung-Bae, Petry, Vanessa, Huang, Chiun-Sheng, Li, Wei, Frenel, Jean-Sebastien, Antolin, Silvia, Yeo, Winnie, Bianchini, Giampaolo, Loi, Sherene, Tsurutani, Junji, Egorov, Anton, Liu, Yali, Cathcart, Jillian, Ashfaque, Shahid, Cortés, Javier

Source: In The Lancet 14-20 January 2023 401(10371):105-117

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Authors: Sánchez-Conde, Matilde, Vizcarra, Pilar, Pérez-García, José Manuel, Gion, María, Martialay, María Pilar, Taboada, Javier, Alonso-Fernández, Alberto, Sampayo-Cordero, Miguel, Malfettone, Andrea, Tena, Isabel, Torre, Sergio De La, Llombart-Cussac, Antonio, Cortés, Javier

Source: In International Journal of Infectious Diseases October 2022 123:97-103

Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study

Authors: Pérez-García, José Manuel, Gebhart, Geraldine, Borrego, Manuel Ruiz, Schmid, Peter, Marmé, Frederik, Prat, Aleix, Dalenc, Florence, Kerrou, Khaldoun, Colleoni, Marco, Braga, Sofía, Malfettone, Andrea, Sampayo-Cordero, Miguel, Cortés, Javier, Llombart-Cussac, Antonio

Source: Future oncology. 18(33):3677-3688

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191696545.0x000001&indx=1&recIds=ETOCvdc_100191696545.0x000001

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Authors: Pérez-García, José Manuel, Gebhart, Geraldine, Ruiz Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Schmid, Peter, Marmé, Frederik, Escrivá-de-Romani, Santiago, Calvo, Lourdes, Ribelles, Nuria, Martinez, Noelia, Albacar, Cinta, Prat, Aleix, Dalenc, Florence, Kerrou, Khaldoun, Colleoni, Marco, Afonso, Noemia, Di Cosimo, Serena, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier ^{*, *}, Llombart-Cussac, Antonio ^*

Source: In The Lancet Oncology June 2021 22(6):858-871

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Authors: Serrano García, Lucía, Jávega, Beatriz, Llombart Cussac, Antonio, Gión, María, Pérez-García, José Manuel, Cortés, Javier, Fernández-Murga, María Leonor

Source: Frontiers in Immunology; 2024, p1-24, 24p

Subject Terms: TRIPLE-negative breast cancer, IMMUNE checkpoint inhibitors, BREAST cancer, PROGESTERONE receptors, ESTROGEN receptors

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

Authors: Ortega, Vanesa, Antón, Antonio, Garau, Isabel, Afonso, Noemia, Calvo, Lourdes, Fernández, Yolanda, Martínez-García, María, Blanco, Esperanza, Zamora, Pilar, García, Mirta, Illarramendi, José Juan, Rodríguez Sánchez, César Augusto, Sampayo, Miguel, Aguirre, Elena, Pérez-García, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

Source: In Clinical Breast Cancer April 2019 19(2):105-112

Clinicopathological and molecular predictors of [¹⁸F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

Authors: Llombart-Cussac, Antonio, Prat, Aleix, Pérez-García, José Manuel, Mateos, José, Pascual, Tomás, Escrivà-de-Romani, Santiago, Stradella, Agostina, Ruiz-Borrego, Manuel, de las Heras, Begoña Bermejo, Keyaerts, Marleen, Galvan, Patricia, Brasó-Maristany, Fara, García-Mosquera, Juan José, Guiot, Thomas, Gion, María, Sampayo-Cordero, Miguel, Di Cosimo, Serena, Pérez-Escuredo, Jhudit, de Frutos, Manuel Atienza, Cortés, Javier

Source: European Journal of Nuclear Medicine & Molecular Imaging; Jul2024, Vol. 51 Issue 9, p2733-2743, 11p

Subject Terms: BREAST, HER2 positive breast cancer, EARLY diagnosis, MAGNETIC resonance imaging, HER2 protein, NEOADJUVANT chemotherapy

Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept

Authors: Ciruelos, Eva, Pérez-García, José Manuel, Gavilá, Joaquín, Rodríguez, Analía, de la Haba-Rodriguez, Juan

Source: Clinical drug investigation. 39(7):595-606

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130228516.0x000001&indx=1&recIds=ETOCvdc_100130228516.0x000001

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients

Authors: Peg, Vicente, Sansano, Irene, Vieites, Begoña, Bernet, Laia, Cano, Rafael, Córdoba, Alicia, Sancho, Magdalena, Martín, María Dolores, Vilardell, Felip, Cazorla, Alicia, Espinosa-Bravo, Martín, Pérez-García, José Manuel, Cortés, Javier, Rubio, Isabel T., Ramón y Cajal, Santiago

Source: In The Breast June 2017 33:8-13

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.

Authors: Gion, María, García-Mosquera, Juan José, Pérez-García, José Manuel, Peg, Vicente, Ruiz-Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Guerrero, José Antonio, López-Montero, Laura, Mancino, Mario, Rodríguez-Morató, José, Antonarelli, Gabriele, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio, Cortés, Javier

Source: Breast Cancer Research & Treatment; Jun2024, Vol. 205 Issue 3, p589-598, 10p

Axillary staging based on molecular analysis: Results of the B-CLOSER-II study

Authors: Sansano, Irene, Vieites, Begoña, Sancho de Salas, Magdalena, García, Carmen, Amendoeira, Isabel, Bernet, Laia, Pérez-García, José Manuel, Espinosa-Bravo, Martín, Rubio, Isabel T., Ramón y Cajal, Santiago, Peg, Vicente

Source: Pathology, research and practice. 216(11)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100110987888.0x000001&indx=1&recIds=ETOCvdc_100110987888.0x000001

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and deintensification strategies in breast cancer.

Authors: Sampayo-Cordero, Miguel, Miguel-Huguet, Bernat, Malfettone, Andrea, López-Miranda, Elena, Gion, María, Abad, Elena, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Cortés, Javier

Source: Frontiers in Oncology; 2023, p1-6, 6p

Subject Terms: OVERTREATMENT of cancer, PROOF of concept, EXPERIMENTAL design, BREAST cancer, MAXIMUM likelihood statistics, DISTRIBUTION (Probability theory)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.

Authors: Pérez-García, José Manuel, Batista, Marta Vaz, Cortez, Patricia, Ruiz-Borrego, Manuel, Cejalvo, Juan Miguel, de la Haba-Rodriguez, Juan, Garrigós, Laia, Racca, Fabricio, Servitja, Sonia, Blanch, Salvador, Gion, María, Nave, Monica, Fernández-Abad, María, Martinez-Bueno, Alejandro, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, Braga, Sofía

Source: Neuro-Oncology; Jan2023, Vol. 25 Issue 1, p157-166, 10p